Skip to main content
EVGN
NASDAQ Industrial Applications And Services

Evogene Q2 Loss Narrows to $1.8M; Cash Burn Cut to $8.5–$9.5M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.6
Mkt Cap
$8.849M
52W Low
$0.37
52W High
$1.5
52W Position info
62% above low
Off High info
60% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

EVGN sits 62% above its 52-week low of $0.37 on light trading volume (0.2× avg).

Summary

Evogene reported a narrower Q2 net loss of $1.8M and cut 2026 cash burn guidance to $8.5–$9.5M, backed by $9.3M in cash and six drug discovery collaborations.


Key Events · Earnings and Guidance · EVGN

  • Q2 Net Loss Narrows to $1.8M

    Net loss for Q2 2026 was $1.8M, down from $4.7M in Q2 2025, driven by lower operating expenses and reduced losses from discontinued operations.

  • Cash Burn Guidance Cut to $8.5–$9.5M

    Full-year 2026 cash usage is expected to be $8.5–$9.5M, down from $14.4M in 2025 and $20.5M in 2024, with further reductions targeted for 2027.

  • Cash Position of $9.3M

    Consolidated cash and cash equivalents were $9.3M as of June 30, 2026, with Q2 cash usage of approximately $2.1M.

  • Six Active Drug Collaborations

    Evogene has six active drug development collaborations with biotech companies and academic institutions, with two programs completing initial Hit Identification with validation results exceeding partner expectations.


Analysis · EVGN · Industrial Applications And Services

A sharply reduced net loss of $1.8 million versus $4.7 million a year ago underscores the impact of aggressive cost cuts that shrank the workforce from 117 to 38 employees. Full-year cash burn is now expected at $8.5–$9.5 million, down from $14.4 million in 2025, extending the runway with $9.3 million in cash. Six active drug discovery collaborations and a 300% expansion of the AI chemical library to 110 billion molecules offer early commercial validation, yet revenue remains minimal at $0.3 million for the quarter. These results land amid an ongoing activist proxy fight and a highly dilutive ATM program, making the improved cash efficiency a critical survival signal.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVGN was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVGN - Latest Insights

EVGN
Nov 19, 2026, 7:12 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.3233
Real-time Price: $0.313 info
Change: -$0.0103 (-3%) info
Market Cap: $5.708M info
EVGN
Nov 16, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3646
Real-time Price: $0.313 info
Change: -$0.0516 (-14%) info
Market Cap: $5.708M info
EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.4101
Real-time Price: $0.313 info
Change: -$0.0971 (-24%) info
Market Cap: $5.708M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.313 info
Change: -$0.1038 (-25%) info
Market Cap: $5.708M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.313 info
Change: -$0.0777 (-20%) info
Market Cap: $5.708M info